Trial Profile
An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 23 Jun 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 23 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2008 Planned end date changed from 1 Aug 2008 to 1 Jan 2009 as reported by ClinicalTrials.gov.